Deletion of p53 in MSCs significantly prolonged mice’s survival beyond discontinuation of therapy (p < 0.003), suggesting that survival of AML cells in response to DS-5272 might depend on p53 levels in MSCs (Figure 4C). Here, TP53 is linked to acute myeloid leukemia.